Talphera Hits Key Milestone in CRRT Study as Market Opportunity Expands — Talphera, Inc.

Event summary

Talphera's NEPHRO CRRT clinical study is now 75% enrolled, on track for completion by year-end.
KDIGO 2026 guidelines cite nafamostat as an acceptable CRRT anticoagulant, a positive shift from prior recommendations.
Updated market research indicates approximately 200,000 annual U.S. CRRT procedures in 2027, up 21% from previous estimates.
Talphera's cash and investments stood at $17.1 million as of June 30, 2026.

The big picture

Talphera's progress in its NEPHRO CRRT study comes amid growing recognition of nafamostat's potential as a regional anticoagulant for continuous renal replacement therapy. The updated KDIGO guidelines and expanded market estimates suggest increasing acceptance of the treatment modality, which could position Talphera favorably if it secures regulatory approval. The company's ability to maintain its cash runway while advancing its clinical program will be critical in the coming months.

What we're watching

Regulatory Tailwinds: Whether the favorable KDIGO guideline inclusion will accelerate nafamostat's regulatory approval process.
Market Potential: How the 21% increase in estimated CRRT procedures could expand nafamostat's commercial opportunity if approved.
Execution Risk: The pace at which Talphera can complete enrollment and finalize study results by year-end.